Ori, a company focused on automated cell therapy manufacturing, has locked down a $120 million pact to deploy its automated production platform for a commercial cell therapy. The therapy itself and the partner involved have not been disclosed, according to Fierce Pharma.
The deal places Ori in a contrasting position to another key player in the automated cell therapy manufacturing space that is currently grappling with a recent setback. Despite that turbulence, Ori's commercial agreement suggests that automated production platforms remain attractive to cell therapy developers looking to scale manufacturing.
With only one source, there is no conflicting reporting to compare. The news, as presented, highlights both the promise and the uneven landscape of automated cell therapy manufacturing.